Summary
Immunotherapy is transforming small cell lung cancer treatment, improving survival in both early and advanced stages, with new drugs offering long-term disease control.
Small cell lung cancer is one of the most aggressive forms of cancer, and for a long time, treatment options were limited. But according to Dr. Jacob Sands of Dana-Farber Cancer Institute, that is starting to change — and in a big way.
For patients with limited-stage small cell lung cancer, where doctors are still trying to cure the disease, treatment used to stop after chemotherapy and radiation. Now, patients also receive two years of immunotherapy — a 30-minute infusion once every four weeks. Most patients handle it well, with far fewer side effects than chemotherapy. Early results show that patients are going longer without the cancer coming back, and Dr. Sands believes more patients may actually be cured, though longer follow-up data is still needed to say that with full confidence.
In advanced, or extensive-stage, small cell lung cancer, immunotherapy has already been part of standard care for about seven or eight years. But new treatments are adding even more options for patients. One exciting development is a class of drugs called antibody-drug conjugates. Think of it like a guided missile: an antibody locks onto a specific target on the tumor cell and delivers chemotherapy directly to it, reducing damage to healthy cells. Multiple drugs using this approach are showing strong results for patients who have already tried other treatments.
Another major advance is a drug called Imdelltra (tarlatamab). It works by grabbing onto both tumor cells and immune cells at the same time, essentially bringing them together so the immune system can attack the cancer more effectively. It has become the go-to second-line treatment option, and some patients are experiencing lasting disease control years after starting it.
